SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

6 Months Ended

Jun. 30, 2023

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Schedule of estimated useful lives of property, plant and equipment

Production equipment	3 to 13 years
Office furniture and equipment	3 to 10 years
Buildings	39 years
Building improvements	15 years

Schedule of significant customers

	Three Months Ended			Three Months Ended			Six Months Ended			Six Months Ended
	June 30, 2023			June 30, 2022			June 30, 2023			June 30, 2022
Number of significant customers		3			3			3			4
Aggregate dollar amount of net sales to significant customers	$	4.4	million	$	8.3	million	$	10.2	million	$	44.4	million
Percentage of net sales to significant customers		55.0%			57.6%			53.9%			75.2%

Schedule of disaggregated information of revenue recognized from contracts with customers and licensing fees recognized

	For the three months ended June 30, 2023:
			Blood						Total
			Collection		EasyPoint®		Other		Product
Geographic Segment	Syringes		Products		Needles		Products		Sales
U.S. sales	$	5,780,080	$	346,297	$	1,165,634	$	8,665	$	7,300,676
Sales to U.S. government		—		—		—		—		—
North and South America sales (excluding U.S.)		210,232		—		—		—		210,232
Other international sales		366,312		1,748		87,612		4,700		460,372
Total	$	6,356,624	$	348,045	$	1,253,246	$	13,365	$	7,971,280

	For the three months ended June 30, 2022:
			Blood						Total
			Collection		EasyPoint®		Other		Product
Geographic Segment	Syringes		Products		Needles		Products		Sales
U.S. sales (excluding U.S. government)	$	6,877,166	$	526,256	$	2,138,573	$	19,814	$	9,561,809
Sales to U.S. government		—		—		—		—		—
North and South America sales (excluding U.S.)		4,096,984		—		—		216,144		4,313,128
Other international sales		423,578		35,246		2,808		—		461,632
Total	$	11,397,728	$	561,502	$	2,141,381	$	235,958	$	14,336,569

	For the six months ended June 30, 2023:
			Blood						Total
			Collection		EasyPoint®		Other		Product
Geographic Segment	Syringes		Products		Needles		Products		Sales
U.S. sales (excluding U.S. government)	$	10,583,166	$	744,673	$	1,378,121	$	18,164	$	12,724,124
Sales to U.S. government		—		—		—		—		—
North and South America sales (excluding U.S.)		4,771,512		—		—		212,040		4,983,552
Other international sales		871,854		213,948		174,204		4,700		1,264,706
Total	$	16,226,532	$	958,621	$	1,552,325	$	234,904	$	18,972,382

	For the six months ended June 30, 2022:
			Blood						Total
			Collection		EasyPoint®		Other		Product
Geographic Segment	Syringes		Products		Needles		Products		Sales
U.S. sales (excluding U.S. government)	$	15,272,468		1,603,951		2,868,543		29,688	$	19,774,650
Sales to U.S. government		15,731,136		—		—		—		15,731,136
North and South America sales (excluding U.S.)		15,171,230		—		2,608		216,418		15,390,256
Other international sales		7,929,017		246,614		5,696		1,550		8,182,877
Total	$	54,103,851	$	1,850,565	$	2,876,847	$	247,656	$	59,078,919

Schedule of diluted EPS under the treasury stock method

	Three Months Ended	Three Months Ended	Six Months Ended	Six Months Ended
	June 30, 2023	June 30, 2022	June 30, 2023	June 30, 2022
Common Stock underlying issued and outstanding stock options	16,033	78,322	22,041	88,347
Common stock issuable upon the conversion of convertible preferred shares	—	232,445	—	232,445
	16,033	310,767	22,041	320,792

Schedule of earnings per share

	Three Months Ended		Three Months Ended		Six Months Ended		Six Months Ended
	June 30, 2023		June 30, 2022		June 30, 2023		June 30, 2022
Net income (loss)	$	(3,868,568)	$	(3,641,597)	$	(2,877,596)	$	3,974,858
Preferred stock dividend requirements		(58,111)		(58,111)		(116,222)		(116,222)
Income (loss) applicable to common shareholders	$	(3,926,679)	$	(3,699,708)	$	(2,993,818)	$	3,858,636
Average common shares outstanding		29,937,159		32,945,821		29,937,159		33,105,637
Average common and common equivalent shares outstanding — assuming dilution		30,169,604		33,256,588		30,169,604		33,426,429
Basic earnings (loss) per share	$	(0.13)	$	(0.11)	$	(0.10)	$	0.12
Diluted earnings (loss) per share	$	(0.13)	$	(0.11)	$	(0.10)	$	0.12